Role of Jun and Jun kinase in resistance of cancer cells to therapy

Drug Resistance Updates

Volumn 6, Issue 3, 2003, Pages 147-156

  Vasilevskaya, Irina ^a   O'Dwyer, Peter J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; C Jun; Cisplatin; Drug resistance; JNK; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOCHROME C; CYTOTOXIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; CANCER CELL; CELL CYCLE; CELL PROLIFERATION; CELL TYPE; DNA DAMAGE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME RELEASE; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METAZOON; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN INTERACTION; REVIEW;

EID: 0038037108     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(03)00043-8     Document Type: Article

References (85)

1. Ababi, S., Maier, R.V., 2002. Mitogen-activated protein kinases. Crit. Care Med. 30, S74-S79.
2. Anderson, S.M., Reyland, M.E., Hunter, S., Deisher, L.M., Barzen, K.A., Quissell, D.Q., 1999. Etoposide-induced activation of c-jun N-terminal kinase (JNK) correlates with drug induced apoptosis in salivary gland acinar cells. Cell Death Differ. 6, 454-462.
3. Aoki, H., Kang, P.M., Hampe, J., Yoshimura, K., Noma, T., Matsuzaki, M., Izumo, S., 2002. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J. Biol. Chem. 277, 10244-10250.
4. Benhar, M., Dalyot, I., Engalberg, D., Levitzki, A., 2001. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol. Cell. Biol. 21, 6913-6926.
5. Blatt, N.B., Glick, G.D., 2001. Signaling pathways and effector mechanisms pre-programmed cell death. Bioorg. Med. Chem. 9, 1371-1384.
6. Boldt, S., Weidle, U.H., Kolh, W., 2002. The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 23, 1831-1838.
7. Brabec, V., Kasparkova, J., 2002. Molecular aspects of resistance to antitumor platinum drugs. Drug Resist. Update 5, 147-161.
8. 2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol. Cell. Biol. 21, 2743-2754.
9. Chang, L., Karin, M., 2001. Mammalian MAP kinase signaling cascades. Nature 410, 37-40.
10. Chen, Z., Seimiya, H., Naito, M., et al., 1999. ASK1 mediates apoptotic cell death induced by genotoxic stress. Oncogene 18, 173-180.
11. Darnell, J.E., 2002. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2, 740-749.
12. Davis, R., 2000. Signal transduction by the JNK group of MAP kinases. Cell 103, 239-252.
13. Donovan, N., Becker, E.B.E., Konishi, Y., Bonni, A., 2002. JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery. J. Biol. Chem. 277, 40944-40949.
14. Eichhorst, S.T., Muller, M., Li-Weber, M., Schulze-Bergkamen, H., Angel, P., Krammer, P.H., 2000. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol. Cell. Biol. 20, 7826-7837.
15. Fan, M., Chambers, T.C., 2001. Role of niitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist. Update 5, 253-267.
16. L are mediated by JNK and occur in parallel with inactivation of Raf-1/MEK/ERK cascade. J. Biol. Chem. 275, 29980-29985.
17. 2-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine. Cancer Res. 61, 4450-4458.
18. Faris, M., Kokot, N., Latinis, K., Kasibhatla, S., Green, D.R., Koretzky, G.A., Nel, A., 1998. The c-Jun N-terminal kinase cascade plays a role in stress-induced apoptosis in Jurkat cells by up-regulating Fas ligand expression. J. Immunol. 160, 134-144.
19. Gallo, K.A., Johnson, G.L., 2002. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell. Biol. 3, 663-672.
20. Gibson, S., Widmann, C., Johnson, G.L., 1999. Differential involvement of MEK kinase 1 (MEKK1) in the induction of apoptosis in response to microtubule-targeted drugs versus DNA damaging agents. J. Biol. Chem. 274, 10916-10922.
21. Gjerset, R.A., Lebedeva, S., Haghigni, A., Turia, S.T., Mercola, D., 1999. Inhibition of Jun kinase pathway blocks DNA repair, enhances p53-mediated apoptosis and promotes gene amplification. Cell Growth Differ. 10, 545-554.
22. Hayakawa, J., Ohmich, M., Kurachi, H., et al., 1999. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitized human ovarian cancer cell line. J. Biol. Chem. 274, 31648-31654.
23. 2-terminal Jun kinase (JNK) by DNA-damaging agents serves to promote drug resistance via phospho-ATF2-dependent enhanced DNA repair. J. Biol. Chem. 10.1074/jbc.M210992200.
24. Hazzalin, C.A., Mahadevan, L.C., 2001. MAPK-regulated transcription: a continuously variable gene switch? Nat. Rev. Mol. Cell. Biol. 3, 30-40.
25. Herr, I., Debafin, K.-M., 2001. Cellular stress response and apoptosis in cancer therapy. Blood 98, 2603-2614.
26. Ichijo, H., 1999. From receptors to stress-activated MAP kinases. Oncogene 18, 6087-6093.
27. Jarpe, M.B., Widmann, C., Knall, C., et al., 1998. Anti-apoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death. Oncogene 17, 1475-1482.
28. Johnson, G.L., Lapadat, R., 2002. Mitogen-activated protein kinase pathways mediated by ERK, JNK and p38 protein kinases. Science 298, 1911-1912.
29. Kallunki, T., Deng, T., Hibi, M., Karin, M., 1996. c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 87, 929-939.
30. Kharbanda, S., Pandey, P., Yamauchi, T., et al., 2000a. Activation of MEK kinase by the c-Abl protein tyrosine kinase in response to DNA damage. Mol. Cell. Biol. 20, 4979-4989.
31. L in response to DNA damage. J. Biol. Chem. 275, 322-327.
32. Kim, R., Ohi, Y., Inoue, H., Toge, T., 2000. Enhancement of chemotherapeutic agents induced-apoptosis associated with activation of c-Jun N-terminal kinase 1 and caspase 3 (CPP32) in bax-transfected gastric cancer cells. Anticancer Res. 20, 439-444.
33. Kim, P.K.M., Mahidhara, R., Seol, D.-W., 2001. The role of caspase-8 in resistance to cancer chemotherapy. Drug Resist. Update 4, 293-296.
34. Kobayashi, K., Tsukamoto, I., 2001. Prolonged Jun N-terminal kinase (JNK) activation and the upregulation of p53 and p21 (WAF1/CIP1) preceded apoptosis in hepatocytes after partial hepatectomy and cisplatin. Biochim. Biophys. Acta 1537, 79-88.
35. Kolbus, A., Herr, I., Schreiber, M., Debatin, K.M., Wagner, E.F., Angel, P., 2000. c-Jun dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents. Mol. Cell. Biol. 20, 575-582.
36. Kolfschoten, G.M., Hulscher, T.M., Duyndam, M.C., Pinedo, H.M., Boven, E., 2002. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer lines as a response to docetaxel. Biochem. Pharmacol. 63, 733-743.
37. Koo, M.S., Kwo, Y.G., Park, J.H., Choi, W.J., Billiar, T.R., Kim, Y.M., 2002. Signaling and function of caspase and c-Jun N-terminal kinase in cisplatin-induced apoptosis. Mol. Cells 13, 194-201. Kyriakis, J.M., Avruch, J., 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81, 807-869.
38. 2-terminal kinase (JNK/SAPK). J. Biol. Chem. 273, 28253-28260.
39. Lee, F.S., Peters, R.T., Dang, L.C., Maniatis, T., 1998b. MEKK1 activates both IkB kinase alpha and IkB kinase beta. Proc. Natl. Acad. Sci. U.S.A. 95, 9319-9324.
40. 2-terminal kinase. Mol. Cell. Biol. 22, 4929-4942.
41. Le-Niculescu, H., Bonfoco, E., Kasuya, Y., Claret, F.-X., Green, D.R., Karin, M., 1999. Withdrawal of survival factors results in activation of JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol. Cell. Biol. 19, 751-763.
42. Leppa, S., Bohmann, D., 1999. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 18, 6158-6162.
43. Levresse, V., Marek, L., Blumberg, D., Heasley, L.E., 2002. Regulation of platinum-compound cytotoxicity by the c-Jun N-terminal kinase and c-Jun signaling pathway in small-cell lung cancer cells. Mol. Pharmacol. 62, 689-697.
44. Li, Q., Gardner, K., Zhang, L., Tsang, B., Bostick-Bruton, F., Reed, E., 1998. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J. Biol. Chem. 273, 23419-23425.
45. Li, Q., Tsang, B., Bostick-Bruton, F., Reed, E., 1999. Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells. Biochem. Pharmacol. 15, 347-353.
46. Lowes, V.L., Ip, N.Y., Wong, Y.H., 2002. Integration of signals from receptor tyrosin kinases and G protein-coupled receptors. Neurosignals 11, 5-19.
47. Mansouri, A., Ridgway, L.D., Korapati, A.L., Zhang, Q., Tian, L., Wang, Y., Siddik, Z.H., Mills, G.B., Claret, F.X., 2003. Sustained activation of JNK-p38 MAP kinase pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J. Biol. Chem. M208134200.
48. Noguchi, K., Kitanaka, C., Yamana, H., Kokubu, A., Mochuzuki, T., Kuchino, Y., 1999. Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J. Biol. Chem. 274, 32580-32587.
49. Onoda, N., Nehmi, A., Weiner, D., Mujumdar, S., Christen, R., Los, G., 2001. Nicotine affects the signaling of the death pathway, reducing the response of head and neck cancer cell lines to DNA damaging agents. Head Neck 23, 860-870.
50. Pan, B., Yao, K.-S., Monia, B.P., Dean, N.M., McKay, R.A., Hamilton, T.C., O'Dwyer, P.J., 2002. Reversal of cisplatin resistance by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. Biochem. Pharmacol. 63, 1699-1707.
51. Park, J., Kim, I., Young, J.O., Lee, K.-W., Han, P.-L., Choi, E.J., 1997. Activation of c-Jun N-terminal kinase antagonizes an anti-apoptotic action of bcl-2. J. Biol. Chem. 272, 16725-16728.
52. Park, S.-H., Zarrinpar, A., Lim, W.A., 2003. Rewiring MAP kinase pathways using alternative scaffold assembly mechanisms. Science 299, 1061-1064.
53. Potapova, O., Haghighi, A., Bost, F., Liu, C., Birrer, M.J., Gjerset, R., Mercola, D., 1997. The JNK/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J. Biol. Chem. 272, 14041-14044.
54. Potapova, O., Basu, S., Mercola, D., Holbrook, N.J., 2001. Protective role for c-Jun in the cellular response to DNA damage. J. Biol. Chem. 267, 28546-28553.
55. Ptashne, M., Gann, A., 2003. Imposing specificity on kinases. Science 299, 1025-1027.
56. Recio, J.A., Paez, J.G., Sanders, S., Kawakami, T., Notario, V., 2002. Partial depletion of intracellular ATP mediates stress survival function of the PCPH oncoprotein. Cancer Res. 62, 2690-2694.
57. Sanchez-Perez, I., Perona, R., 1999. Lack of c-Jun activity increases survival to cisplatin. FEBS Lett. 453, 151-158.
58. Sanchez-Perez, I., Murguia, J.R., Perona, R., 1998. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16, 533-540.
59. Sanchez-Perez, I., Martinez-Gomariz, M., Williams, D., Keyse, S.M., Perona, R., 2000. CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene 19, 5142-5152.
60. Sanchez-Perez, I., Benitah, S.A., Martinez-Gomariz, M., Lacal, J.C., Perona, R., 2002. Cell stress and MEKK1-mediated c-Jun activation modulate NFkB activity and cell viability. Mol. Biol. Cell 13, 2933-2945.
61. Schlessinger, J., 2000. Cell signaling by receptor tyrosine kinases. Cell 103, 211-225.
62. 2-terminal kinase-mediated activation of interleukin-lbeta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J. Biol. Chem. 272, 4631-4636.
63. Shiah, S.-G., Chuang, S.-E., Kuo, M.-L., 2001. Involvement of Asp-GluVal-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. Mol. Pharmacol. 59, 254-262.
64. Shtil, A.A., Mandlekar, S., Yu, R., Walter, R.J., Hagen, K., Tan, T.H., Roninson, I.B., Kong, A.N., 1999. Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells. Oncogene 18, 377-384.
65. Srivastava, R.K., Mi, Q.S., Hardwick, J.M., Longo, D.L., 1999. Deletion of the loop region of bcl-2 completely blocks paclitaxel-induced apoptosis. Proc. Natl. Acad. Sci. U.S.A. 96, 3775-3780.
66. Stone, A.A., Chambers, T.C., 2000. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp. Cell Res. 254, 110-119.
67. Takaesu, G., Surabhi, R.M., Park, K.J., Ninomiya-Tsuji, J., Matsumoto, K., Gaynor, R.B., 2003. TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. J. Mol. Biol. 326, 105-115.
68. Tournier, C., Hess, P., Yang, D.D., Xu, J., et al., 2000. Requirement of JNK for stress-induced activation of cytochrome c-mediated death pathway. Science 288, 870-874.
69. Wang, T.-H., Wang, H.-S., Ichijo, H., Giannakakou, P., Foster, J.S., Fojo, T., Wimalasena, J., 1998. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated kinase through both Ras and apoptosis signal-regulating kinase pathways. J. Biol. Chem. 273, 4928-4936.
70. Wang, T.-H., Popp, D.M., Wang, H.-S., Saitoh, M., Mural, J.G., Henley, D.C., Ichijo, H., Wimalasena, J., 1999. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal (JNK)-dependent and -independent pathways in ovarian cancer cells. J. Biol. Chem. 274, 8208-8216.
71. Wang, T.-H., Wang, H.-S., Soong, Y.-K., 2000. Paclitaxel-induced cell death. Cancer 88, 2619-2628.
72. West, K.A., Castillo, S.S., Dennis, P.A., 2002. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Update 5, 234-248.
73. Weston, C.R., Davis, R.J., 2002. The JNK signal transduction pathway. Curr. Opin. Genet. Dev. 12, 14-21.
74. Whitmarsh, A.J., Cavanagh, J., Tournier, C., Yasuda, J., Davis, R.J., 1999. A mammalian scaffold complex that selectively mediates MAP kinase activation. Science 281, 1671-1674.
75. Xia, Z., Dickens, M., Raingeaud, J., Davis, R.J., Greenberg, M.E., 1995. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270, 1326-1331.
76. Xia, Y., Makris, C., Su, B., Li, E., Yang, J., Nemerow, G.R., Karin, M., 2000. MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration. Proc. Natl. Acad. Sci. U.S.A. 97, 5243-5248.
77. Xu, Z., Kukekov, N.V., Greene, L.A., 2003. POSH acts as a scaffold for a multiprotein complex that mediates JNK activation in apoptosis. EMBO J. 22, 252-261.
78. 2/M. Mol. Cell. Biol. 19, 8469-8478.
79. Yang, J., Lin, Y., Guo, Z., et al., 2001. The essential role of MEKK3 in TNF-induced NF-kappaB activation. Nat. Immunol. 2, 620-624.
80. Yoshida, S., Kawaguchi, H., Sato, S., Ueda, R., Furukawa, K., 2002. An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation. Jpn. J. Cancer Res. 93, 816-824.
81. Yuan, Z.-Q., Feldman, R.I., Sussman, G.E., Coppola, D., Nicosia, S.V., Cheng, J.Q., 2003. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASKI: implication of AKT2 in chemoresistance. J. Biol. Chem. 10.1074/jbc M302674200.
82. Zagariya, A., Mungre, S., Lovis, R., Birrer, M., Ness, S., Thimmapaya, B., Pope, R., 2000. Tumor necrosis alpha gene regulation: enhancement of C/EBPb-induced activation by c-Jun. Mol. Cell. Biol. 18, 2815-2824.
83. Zanke, B.W., Boudreau, K., Rubie, E., et al., 1996. The stress-activated protein kinase pathway mediates cell death following injury by cis-platinum, UV irradiation or heat. Curr. Biol. 6, 606-613.
84. Zhao, Q., Lee, F.S., 1999. Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-kappaB through IkappaB kinase-alpha and IkappaB kinase-beta. J. Biol. Chem. 274, 8355-8358.
85. Zhou, G., Bao, Z.Q., Dixon, J.E., 1995. Components of a new human protein kinase signal transduction pathway. J. Biol. Chem. 270, 12665-12669.